Picture a cancer silently on the rise, striking men at nearly twice the rate of women, as kidney cancer is projected to be diagnosed in over 81,000 Americans this year alone.
Key Takeaways
- In 2024, an estimated 81,610 new cases of kidney and renal pelvis cancer will be diagnosed in the United States, including 52,220 in men and 29,390 in women.
- Kidney cancer accounts for approximately 3.4% of all new cancer cases in the US in 2024.
- The lifetime risk of developing kidney cancer is 1 in 47 for men and 1 in 80 for women in the US.
- Smoking is responsible for 15-30% of renal cell carcinoma cases.
- Obesity increases kidney cancer risk by 24% per 5 kg/m² BMI increase.
- Hypertension raises kidney cancer risk by 28% according to meta-analysis.
- Gross hematuria is the presenting symptom in 40-60% of kidney cancer cases.
- Flank pain occurs in 40% of patients at diagnosis.
- Palpable abdominal mass in 25-45% of advanced cases.
- Nephrectomy is primary treatment for 60-70% localized.
- Partial nephrectomy preferred for T1 tumors, preserving function.
- Sunitinib first-line for metastatic RCC, PFS 11 months.
- Overall 5-year survival for kidney cancer is 76% in US 2014-2020.
- Localized kidney cancer 5-year survival 93%.
- Regional spread 5-year survival 72%.
Kidney cancer is a globally significant disease with distinct gender and geographical variations.
Incidence and Prevalence
- In 2024, an estimated 81,610 new cases of kidney and renal pelvis cancer will be diagnosed in the United States, including 52,220 in men and 29,390 in women.
- Kidney cancer accounts for approximately 3.4% of all new cancer cases in the US in 2024.
- The lifetime risk of developing kidney cancer is 1 in 47 for men and 1 in 80 for women in the US.
- Globally, there were 431,288 new cases of kidney cancer in 2022 according to GLOBOCAN estimates.
- Kidney cancer incidence rate is 17.9 per 100,000 men and 9.5 per 100,000 women worldwide in 2022.
- In the European Union, kidney cancer incidence is highest in Lithuania at 20.9 per 100,000 in men.
- US age-adjusted incidence rate for kidney cancer was 16.8 per 100,000 in 2019-2023.
- Among US non-Hispanic White males, kidney cancer incidence is 20.6 per 100,000.
- Kidney cancer prevalence in the US is estimated at 522,345 survivors as of 2022.
- Incidence of renal cell carcinoma, the most common type, is 14.6 per 100,000 in the US.
- In China, kidney cancer new cases reached 76,760 in 2022.
- Czech Republic has one of the highest kidney cancer rates at 18.1 per 100,000 overall.
- Kidney cancer incidence among US Black males is 18.2 per 100,000.
- From 2013-2022, kidney cancer incidence increased by 0.7% annually in the US.
- In Japan, kidney cancer cases numbered 25,177 in 2022.
- US females have a kidney cancer incidence of 10.0 per 100,000 age-adjusted.
- Northern America has the highest regional incidence at 16.6 per 100,000.
- Kidney cancer is the 9th most common cancer globally for incidence.
- In Australia, incidence rate is 14.7 per 100,000 for kidney cancer.
- US Hispanic females have incidence of 7.8 per 100,000.
- Kidney cancer median age at diagnosis in US is 64 years.
- 81% of kidney cancers are diagnosed at local or regional stage in US.
- In the UK, there were 16,720 new kidney cancer cases in 2017-2019 average.
- Kidney cancer incidence in UK men is 17.9 per 100,000.
- France reports 15,777 new kidney cancer cases in 2022.
- US Asian/Pacific Islander males incidence is 9.4 per 100,000.
- Global prevalence of kidney cancer is about 1.8 million in 2022.
- In Canada, kidney cancer incidence is 15.6 per 100,000.
- Kidney cancer is more common in urban areas with 1.2 times higher incidence.
- Renal pelvis cancer incidence is 1.1 per 100,000 in US.
Incidence and Prevalence Interpretation
While the odds are personally in our favor, collectively we're facing a global tide of kidney cancer, with men statistically shouldering a heavier burden and stark geographical disparities painting a map of unequal risk.
Prognosis and Mortality
- Overall 5-year survival for kidney cancer is 76% in US 2014-2020.
- Localized kidney cancer 5-year survival 93%.
- Regional spread 5-year survival 72%.
- Distant metastatic 5-year survival 17%.
- In 2024, estimated 14,390 deaths from kidney cancer in US.
- Global kidney cancer deaths 179,368 in 2022.
- Mortality rate age-adjusted 3.7 per 100,000 US.
- Fuhrman grade 4 tumors 5-year survival <50%.
- IMDC favorable risk mRCC median OS 43 months.
- IMDC intermediate risk OS 23 months.
- IMDC poor risk OS 8 months untreated.
- Sarcomatoid differentiation worsens prognosis, OS 4-6 months.
- T1 tumors 5-year cancer-specific survival 97%.
- N0 vs N1 lymph node involvement halves survival.
- Bone metastases median survival 12 months.
- Liver metastases OS 8 months.
- MSKCC score 0: OS 38 months, 3+: 5 months.
- 10-year survival 53% overall US.
- Clear cell histology better than papillary, HR 1.3 worse.
- Performance status ECOG 0-1: 80% 1-year survival.
- Elevated neutrophils >4.5 predicts worse OS HR 1.8.
- Anemia Hb<10 g/dL IMDC risk factor.
- Thrombocytosis >upper limit HR 1.5 mortality.
- LDH >1.5x ULN poor prognosis IMDC.
- Post-nephrectomy recurrence 20-30% at 5 years T1b.
- UK kidney cancer mortality 4,566 in 2017-2019.
- Mortality decreasing 1.3% annually 2013-2022 US.
- Men mortality 4.3 per 100,000, women 2.5.
Prognosis and Mortality Interpretation
The crucial story these numbers tell is that catching kidney cancer early offers an excellent chance of survival, but once it spreads aggressively or acquires certain brutal biological features, the fight becomes dramatically tougher, highlighting the urgent need for better treatments for advanced disease.
Risk Factors
- Smoking is responsible for 15-30% of renal cell carcinoma cases.
- Obesity increases kidney cancer risk by 24% per 5 kg/m² BMI increase.
- Hypertension raises kidney cancer risk by 28% according to meta-analysis.
- Family history doubles the risk of kidney cancer in first-degree relatives.
- Current smokers have 50% higher risk of kidney cancer than never smokers.
- Type 2 diabetes mellitus is associated with 42% increased risk of RCC.
- Acquired cystic kidney disease increases risk 30-50 times in dialysis patients.
- Occupational exposure to trichloroethylene raises risk by 30-40%.
- 3-8% of kidney cancers are hereditary, including von Hippel-Lindau syndrome.
- Analgesic abuse, especially phenacetin, increases risk 5-fold historically.
- Heavy metals like cadmium exposure linked to 1.5-2.0 relative risk.
- HIV infection increases kidney cancer risk by 2-3 times.
- Paraneoplastic syndromes occur in 20% of cases, linked to risk factors.
- Alcohol consumption reduces risk by 23% for heavy drinkers meta-analysis.
- Physical activity lowers risk by 12-20% per high activity level.
- Tuberous sclerosis complex carries 2-4% lifetime risk of RCC.
- Birt-Hogg-Dubé syndrome increases risk 15-30 fold.
- Smoking cessation reduces risk gradually, 50% after 10 years quit.
- High red meat intake associated with 19% increased risk per 100g/day.
- Fruit and vegetable intake inversely associated, 14% lower risk high intake.
- Chronic kidney disease stage 3+ increases risk 2-5 fold.
- Hepatitis C virus infection raises risk by 1.5-2.0 times.
- Men have 2 times higher risk than women, possibly hormonal.
- Age over 65 triples risk compared to under 65.
- African American race has 20% higher incidence adjusted for SES.
- Polycystic kidney disease mild elevation in risk, OR 1.6.
- Statin use may reduce risk by 15-20% long-term.
Risk Factors Interpretation
One might say the path to kidney cancer is regrettably well-paved by habits like smoking and overeating, unexpectedly guarded by a moat of red wine, and frustratingly barricaded by a hereditary wall for a unlucky few.
Symptoms and Diagnosis
- Gross hematuria is the presenting symptom in 40-60% of kidney cancer cases.
- Flank pain occurs in 40% of patients at diagnosis.
- Palpable abdominal mass in 25-45% of advanced cases.
- Paraneoplastic syndromes like hypercalcemia in 13-20%.
- Fever without infection in 20% due to IL-6 production.
- Weight loss in 30-40% of symptomatic patients.
- Anemia from erythropoietin dysregulation in 30%.
- Contrast-enhanced CT detects 90-95% of renal masses >3cm.
- MRI sensitivity for renal lesions is 91-100%.
- Ultrasound identifies 80% of solid renal masses.
- Renal biopsy performed in 10-20% of cases preoperatively.
- Clear cell RCC comprises 75-80% of cases on pathology.
- Papillary RCC type 1 and 2 in 15% total.
- Chromophobe RCC 5%, oncocytoma 3-5% benign mimic.
- Bosniak classification: category III cysts 50-60% malignant.
- PET-CT FDG uptake moderate in 60-70% of RCC.
- Incidental discovery on imaging in 50-66% of cases.
- Elevated LDH prognostic in 20% with high levels.
- Varicocele or leg edema from venous invasion in 5-10%.
- Polycythemia from EPO in 1-8% of cases.
- Core biopsy diagnostic accuracy 90-95% for malignancy.
- MSKCC symptoms index correlates with performance status.
- Hematuria microscopic in 20-30% early cases.
- Night sweats and fatigue in 15-20%.
- TNM staging: T1a tumors <4cm in 40% at diagnosis.
- Liquid biopsy ctDNA detects 70% in metastatic RCC.
- 85% of kidney cancers are renal cell carcinomas.
Symptoms and Diagnosis Interpretation
Kidney cancer tends to reveal itself not through a single dramatic announcement but through a persistent, mismatched ensemble cast of symptoms—like a pain in your side, blood in your urine, or unexplained weight loss—but often has the audacity to show up uninvited in half of all cases, discovered purely by chance during an unrelated scan.
Treatment
- Nephrectomy is primary treatment for 60-70% localized.
- Partial nephrectomy preferred for T1 tumors, preserving function.
- Sunitinib first-line for metastatic RCC, PFS 11 months.
- Pembrolizumab + axitinib improves OS by 42% vs sunitinib.
- Nivolumab second-line OS 25 months vs 19.6 everolimus.
- Cabozantinib PFS 7.4 months in pretreated mRCC.
- Stereotactic body radiotherapy (SBRT) local control 95% for metastases.
- Cytoreductive nephrectomy benefit in IMDC intermediate 29%.
- Adjuvant pembrolizumab DFS HR 0.68 in localized high-risk.
- HIF-2a inhibitor belzutifan ORR 25% in VHL-associated.
- Radiofrequency ablation success 90-95% for small tumors.
- Active surveillance for T1a low-risk, growth 0.13cm/year.
- Tivozanib third-line PFS 5.6 months vs 3.9 sorafenib.
- Lenvatinib + everolimus PFS 14.6 months second-line.
- Atezolizumab + bevacizumab non-inferior PFS 13.8 months.
- Ipilimumab + nivolumab CR 11% in first-line poor risk.
- Axitinib monotherapy PFS 6.7 months refractory.
- Pazopanib first-line PFS 8.4 months.
- Microwave ablation recurrence-free 92% at 1 year.
- Everolimus mTOR inhibitor PFS 4.9 months.
- Robotic partial nephrectomy warm ischemia 20-25 min.
- Temsirolimus poor-risk OS 10.9 months.
- HIFU experimental, necrosis 80% in small tumors.
- Sorafenib OS 19.3 months second-line early trial.
- Bevacizumab + IFN PFS 10.2 months.
Treatment Interpretation
While we still often start by taking a kidney out for early disease, the real story is our growing quiver of targeted and immune-based arrows that are turning metastatic kidney cancer from a swift tragedy into a more manageable, chronic chess match.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2GCOgco.iarc.who.intVisit source
- Reference 3ECISecis.jrc.ec.europa.euVisit source
- Reference 4SEERseer.cancer.govVisit source
- Reference 5CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 6CANCERcancer.caVisit source
- Reference 7CANCERcancer.govVisit source
- Reference 8PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 9CDCcdc.govVisit source
- Reference 10KIDNEYkidney.orgVisit source
- Reference 11IARCiarc.who.intVisit source
- Reference 12NCBIncbi.nlm.nih.govVisit source
- Reference 13UPTODATEuptodate.comVisit source
- Reference 14ACRacr.orgVisit source
- Reference 15PUBSpubs.rsna.orgVisit source
- Reference 16AUANETauanet.orgVisit source
- Reference 17PATHOLOGYOUTLINESpathologyoutlines.comVisit source
- Reference 18NEJMnejm.orgVisit source